PT  - JOURNAL ARTICLE
AU  - Moekotte, Lude
AU  - de Boer, Joke H.
AU  - Hiddingh, Sanne
AU  - de Ligt, Aafke
AU  - Nguyen, Xuan-Thanh-An
AU  - Hoyng, Carel B.
AU  - Inglehearn, Chris F.
AU  - McKibbin, Martin
AU  - Lamey, Tina M.
AU  - Thompson, Jennifer A.
AU  - Chen, Fred K.
AU  - McLaren, Terri L.
AU  - AlTalbishi, Alaa
AU  - Panneman, Daan M.
AU  - Boonen, Erica G.M.
AU  - Banfi, Sandro
AU  - Bocquet, Béatrice
AU  - Meunier, Isabelle
AU  - Baere, Elfride De
AU  - Koenekoop, Robert
AU  - Ołdak, Monika
AU  - Rivolta, Carlo
AU  - Roberts, Lisa
AU  - Ramesar, Raj
AU  - Strupaitė-Šileikienė, Rasa
AU  - Kohl, Susanne
AU  - Farrar, G. Jane
AU  - van Vugt, Marion
AU  - van Setten, Jessica
AU  - Roosing, Susanne
AU  - van den Born, L. Ingeborgh
AU  - Boon, Camiel J.F.
AU  - van Genderen, Maria M.
AU  - Kuiper, Jonas J.W.
TI  - Elevated Plasma Complement Factors in <em>CRB1</em>-associated Inherited Retinal Dystrophies
AID  - 10.1101/2023.11.10.23298334
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.10.23298334
4099  - http://medrxiv.org/content/early/2023/11/10/2023.11.10.23298334.short
4100  - http://medrxiv.org/content/early/2023/11/10/2023.11.10.23298334.full
AB  - Objective To determine the profile of inflammation-related proteins and complement system factors in serum of CRB1-associated inherited retinal dystrophies (CRB1-IRDs).Design A case-control study.Subjects, Participants, and/or Controls A cohort of 30 Dutch CRB1-IRD patients and 29 Dutch healthy controls (HC) (Cohort I), and a second cohort of 123 CRB1-IRD patients from 14 countries and 1292 controls (Cohort II) were used in this study.Methods Quantitative 370-plex targeted proteomics in blood plasma and genotyping of the single nucleotide variant (SNV) rs7535263 in the CFH gene.Main Outcome Measures Plasma concentrations of inflammation-related proteins and the genotype of the SNV rs7535263.Results CRB1-IRD patients showed increased plasma levels of complement system and coagulation cascade proteins compared to healthy controls. Complement Factor I [CFI], Serpin Family D1 [SERPIND1], and Complement Factor H [CFH] were significantly elevated (q<0.05, adjusted for age and sex), which correlated (Pearson’s correlation coefficient >0.6) with higher levels of plasma Complement Component 3 [C3] (q = 0.064). The most enriched pathway in patients was the “Complement cascade” (R-HSA-166658, Padj = P = 3.03 × 10-15). An analysis of the genotype of CFH variant rs7535263, which is in close physical proximity to the CRB1 gene and is associated with other retinal conditions by influencing plasma complement levels, revealed significantly skewed allele distribution specifically in Dutch patients (A allele of rs7535263, odds ratio (OR) [95%CI = 2.85 [1.35-6.02], P = 6.19 × 10-3), but not in a global case-control cohort (P = 0.12). However, CRB1 missense variants that are common in patients display strong linkage disequilibrium (LD) with rs7535263 in CFH in the UK Biobank (D’ = 0.97 for p.(Cys948Tyr); D’ = 1.0 for p.(Arg764Cys)), indicating that genetic linkage may influence plasma complement factor levels in CRB1-IRD patients. After accounting for the CFH genotype in the proteomic analyses, we also detected significantly elevated plasma levels of Complement Factor H Related 2 [CFHR2] in CRB1-IRD patients (q = 0.04).Conclusions CRB1-IRDs are characterized by changes in plasma levels of complement factors and proteins of the innate immune system, which is influenced by common functional variants in the CFH-CFHR locus. This indicates that innate immunity is implicated in CRB1-IRDs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Bartimeus Foundation (LM, JHdB, SH, AdL, XN, LIvdB, CB, MMvG, JJWK), VHRN vision health research network and FBC fighting blindness Canada (RK), Swiss National Science Foundation (grant 204285) and European Union (grant EJP-RD19-234, Solve-Ret) (CR)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University Medical Center Utrecht and Radboud University Medical Center gave ethical approval for this work (ethics number MEC-14-065 and MEC-2010-359, respectively).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors